



ASX release

23 February 2017

AtCor Signs Local Health System Agreement ***Opens up opportunities with additional health networks***

AtCor Medical (ASX: ACG), the developer and marketer of SphygmoCor® for advanced hypertension management, today announced it has entered into a three year network agreement with Emory University and Emory Healthcare, Atlanta, GA. Under the agreement, AtCor will provide SphygmoCor systems to Emory-owned and affiliated locations and practices. Up to 40 SphygmoCor systems will be placed during the first 18 months.

Emory is one of the premier integrated delivery networks (IDNs) in the United States, and is ranked among the top cardiology centres by U.S. News and World Report. The Emory Healthcare network includes 6 hospitals, 258 specialty care and 109 primary care locations.

IDNs are local, equity-based health systems that consist of a number of hospitals, outpatient service centres and multi-specialty practices. Depending on the size of a metropolitan market, a number of IDNs will be present and together dominate local healthcare delivery. Securing an agreement with an IDN is a catalyst for other local IDNs to adopt the new technology.

“We are very pleased to strengthen our relationship with the Emory network, the undisputed leading healthcare provider in the region. We have worked for many years with Emory researchers. It is gratifying to see this relationship progress to the hospital and clinic for advanced hypertension management,” said Duncan Ross, AtCor Medical CEO. “The core foundation of AtCor’s clinical growth strategy is to work closely with leading integrated delivery networks.”

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

For personal use only